Tempest Therapeutics, Inc. has announced a reconvened special meeting of stockholders to vote on a significant amendment to its corporate governance. This meeting, initially convened on July 27, 2026, has faced multiple adjournments due to insufficient votes. The company aims to replace certain supermajority voting requirements and allow stockholder action by written consent, which could enhance operational efficiency.
The pharmaceutical preparations company, headquartered in Brisbane, California, trades on the Nasdaq under the ticker symbol TPST. Tempest Therapeutics focuses on developing innovative therapies for cancer treatment. The company has been navigating a complex corporate landscape, as evidenced by its recent filings, including a series of 8-K reports and proxy statements.
According to the recent SEC filing (accession number 0001213900-26-111032), the special meeting will reconvene on November 12, 2026, at 2:00 p.m. Eastern Time. The meeting will be held virtually, allowing stockholders to participate from anywhere. A total of 11,004,101 shares, representing 74.3% of the outstanding shares, were present during the last meeting, but the company decided to adjourn due to insufficient votes.
The proposed amendment requires the affirmative vote of at least 75% of the votes that stockholders would be entitled to cast. This change is seen as a crucial step in modernizing the company's governance structure, which may resonate throughout the pharmaceutical industry, particularly among smaller reporting companies.
Looking ahead, the reconvened special meeting is set for November 12, 2026. Stockholders who have already submitted proxies will have their votes counted unless they choose to revoke them. The outcome of this vote could significantly impact the company's governance and operational agility.